I lead a translational research program in bladder cancer, focusing on the biological mechanisms of disease development, treatment response, and resistance. My group specializes in biomarker discovery and clinical implementation of liquid biopsy technologies, including ctDNA. We conduct prospective biobank studies and interventional trials aimed at developing and validating biomarkers to guide treatment decisions. 

As Chair Professor (ledende professor), I am responsible for research at MOMA and lead a multidisciplinary group in translational bladder cancer research. I am part of the department’s leadership and oversee daily research management, supervision of junior researchers, and project development in collaboration with clinical and international partners. I serve as PI on national clinical trials and as vice-director of the DCCC ctDNA Center.